Last updated: March 14, 2017
Sponsor: Merck Sharp & Dohme Corp.
Overall Status: Completed
Phase
3
Condition
Herpes Simplex Infections
Chickenpox (Varicella Zoster Infection)
Pneumococcal Disease
Treatment
N/AClinical Study ID
NCT00535730
V211-012
2007_592
Ages > 60 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
60 years of age or older
Stable underlying conditions
Postmenopausal if female
Afebrile
Exclusion
Exclusion Criteria:
Previously vaccinated with either vaccine
Immune deficiency
History of allergy to components in either vaccine
Concomitant antiviral therapy
Study Design
Total Participants: 473
Study Start date:
June 01, 2007
Estimated Completion Date:
February 29, 2008